Use of Lidocaine in Rapid Sequence Induction

Hemodynamic Response Clinical Trial

Official title:

Impact of Lidocaine on Anesthetic Depth During Rapid Sequence Induction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01238718
• Other study ID #: lidocaine3
• Status: Completed
• Phase: N/A
• First received: November 8, 2010
• Last updated: August 23, 2011
• Start date: October 2008
• Est. completion date: July 2011

Study information

• Verified date: November 2010
• Source: University of Athens
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lidocaine has been shown to blunt the cardiovascular response to endotracheal intubation. The incidence of hypertension, tachycardia and dysrhythmias due to laryngoscopy may be increased in patients that receive rapid sequence induction and intubation, where opioids are spared and intravenous anesthetic agents are not titrated step by step. Our hypothesis was that lidocaine when administered intravenously in patients who undergo rapid sequence induction may not only blunt the hemodynamic response to intubation, but may also increase the anesthetic depth (as assessed by BIS), thus further reducing the possibility of hypertension, arrhythmias and also awareness.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 76
• Est. completion date: July 2011
• Est. primary completion date: July 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 70 Years

Eligibility

Inclusion Criteria:

• reason for rapid sequence induction (emergency, reflux),

• ASA I-II,

• no antihypertensive drugs,

• no antiarrhythmic drugs

Exclusion Criteria :

Related Conditions & MeSH terms

• Hemodynamic Response

Intervention

Drug:
• Lidocaine
lidocaine 1.5 mg/kg intravenously
• Placebo
normal saline

Locations

Country	Name	City	State
Greece	Aretaieio Hospital, University of Athens	Athens	Attiki

Sponsors (1)

Lead Sponsor	Collaborator
University of Athens

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BIS changes after lidocaine administration in rapid sequence induction		change from baseline in BIS values during 10 minutes
Secondary	change in blood pressure		change from baseline in blood pressure during 10 minutes
Secondary	change in Heart rate		change from baseline in heart rate durng 10 minutes